STAT+: Pharmalittle: We’re reading about an FDA commissioner candidate, Germany’s plans for drug prices, and more
STAT [Unofficial]
June 24, 2026
Regenxbio plans to apply for accelerated approval for its gene therapy for Duchenne muscular dystrophy.
Discussion in the ATmosphere